AZ and Biocompatibles enter GLP-1 alliance; later terminated
AstraZeneca and drug delivery device firm Biocompatibles International PLC have entered into an agreement that gives AZ an exclusive option to license a new discovery-stage glucagon-like peptide (GLP-1; a naturally occurring hormone that stimulates the pancreas to produce insulin) analog and its patents for Type II diabetes and obesity.
- Controlled Release
- Drug Delivery
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com